Skip to main content

Security report for pharmanord.com

Pharma Nord · Healthcare · Denmark

Partial score · DNS & email only

75/100

0–100, higher is better. How it is calculated

Pharma Nord is a medium-sized Danish company specializing in scientifically documented dietary supplements, targeting health-conscious consumers and healthcare professionals. The company operates an e-commerce platform offering well-documented products such as coenzyme Q10, selenium, and chromium. The website demonstrates a professional and consistent brand presence with good content quality and user experience. Technically, the site employs modern JavaScript frameworks and integrates multiple analytics and advertising tools, maintaining moderate performance and good mobile optimization. Security posture is strong with HTTPS enforcement, security headers, and cookie consent mechanisms, although explicit security policies and incident response information are absent. The lack of WHOIS registration data is a notable concern, potentially indicating privacy protection or data unavailability, which slightly impacts trustworthiness. Overall, Pharma Nord's digital presence is robust, with room for improvement in transparency and security disclosures.

Scanned

NIS2 and GDPR posture

GDPR outside view
100/ 100 · Low
Checks completed
6of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

1 finding rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching pharmanord.com

This scan found 13 issues across 4 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Email security
70
DNS health
80
Network security
100
GDPR outside view
100
Average
83
After the cap
75

Not counted

  • Security headers: did not complete in this scan.
  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention pharmanord.com, from OffSeq Breach.

Total records
10
Employees
0
Customers
10
Third parties
0
Weak passwords
30%

4 subdomains affected

See the 10 newest leaked credentials

A one-off add-on to this report that lists the most recent identifier and password pairs OffSeq Breach holds for pharmanord.com.

Select it in the checkout above.

Breach keeps ingesting new leaks, so these numbers can grow between scans.

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Pharma Nord holds a solid position in the European dietary supplement market, leveraging scientific documentation as a competitive advantage. Their business model focuses on direct online sales supported by comprehensive product information and certifications such as GMP and ISO 9001. The company targets a broad audience including consumers and healthcare professionals, with a clear emphasis on quality and trust. The presence of multiple social media channels and advertising partnerships indicates active marketing efforts. However, the absence of public WHOIS data and some missing security disclosures suggest areas for enhanced corporate transparency. The company appears to maintain a medium-sized operational scale with a focus on healthcare and e-commerce sectors.

Security posture

The website exhibits a mature security posture with enforced HTTPS, appropriate security headers, and a cookie consent mechanism aligned with GDPR requirements. No exposed sensitive data or vulnerable libraries were detected. However, the absence of a public security policy, vulnerability disclosure program, or incident response contact channels limits the transparency of their security governance. The use of multiple third-party tracking and advertising scripts introduces potential privacy risks, mitigated by consent mechanisms. Overall, the security maturity is good but could be enhanced by publishing explicit security policies and establishing formal vulnerability disclosure channels.

Recommendations

  1. Publish a dedicated security policy page outlining security practices and compliance.
  2. Implement a vulnerability disclosure program and provide a security.txt file for transparency.
  3. Enhance accessibility features to improve compliance and user experience for all users.
  4. Regularly review and audit third-party scripts to minimize privacy and security risks.
  5. Increase transparency around domain registration and ownership to improve trust.

Contact details published on the site

Addresses
Legal name
Pharma Nord A/S
VAT number
DK 12345678
Registration number
12345678
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Pharma Nord
Description
Scientifically documented dietary supplements. Discover our well documented coq10, selenium and chromium in our webshop.
Key services
Dietary supplements sales, Scientific documentation and product information, Online webshop
Content quality
good
Branding
consistent

Technology

Stack
JavaScript, Google Tag Manager, Facebook Pixel, Bing Ads, Cookie Consent JS
Frameworks
Custom header JS framework (header2020.min.js)
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent with opt-in
  • No exposed sensitive data in HTML
  • Use of security headers

Analytics and tracking

Services
Google Analytics, Local Analytics Cookies
Tracking level
moderate
Privacy practices
good

Advertising

Ad networks
Google Ads, Bing Ads
Tracking pixels
Facebook Pixel
Marketing tools
Facebook Pixel
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and professional design.
  2. Comprehensive cookie and privacy policies with consent mechanisms are implemented.
  3. No WHOIS registration data available, which is unusual for an active commercial domain.
  4. Use of multiple third-party analytics and advertising scripts.
  5. No visible security vulnerabilities or exposed sensitive data.
  6. No explicit security policy or incident response information found.
  7. Good GDPR compliance indicators.
  8. Contact information including email, phone, and address is present and accessible.
Technical notes

Notes

The website uses a custom JavaScript framework for header and navigation, integrates Google Tag Manager, Facebook Pixel, and Bing Ads for analytics and marketing. The site is mobile optimized with responsive design and employs cookie consent scripts for privacy compliance. Performance is moderate with room for optimization. No CMS was explicitly detected, suggesting a custom or proprietary platform. Hosting provider details are not disclosed. The technical implementation is solid with modern practices but could benefit from enhanced accessibility and performance tuning.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with pharmanord.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review pharmanord.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.